TG Therapeutics Inc (TGTX)
TG Therapeutics Inc. is a commercial-stage biopharmaceutical company focused on developing and bringing to market therapies for B-cell mediated diseases in the United States and other international markets. Its commercial product, BRIUMVI, is an anti-CD20 monoclonal antibody approved for adults with relapsing forms of multiple sclerosis, including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease. The company also maintains a pipeline that includes Ublituximab IV for relapsing MS, TG-1701, an oral BTK inhibitor, and TG-1801, a bispecific CD47 and CD19 antibody, along with other investigational medicines. TG Therapeutics has licensing relationships with several partners, including LFB Biotechnologies, GTC Biotherapeutics, LFB/GTC LLC, Ildong Pharmaceutical, and Jiangsu Hengrui Medicine. Incorporated in 1993, it is headquartered in Morrisville, North Carolina.
Jump directly to the stock analysis sections supported by the latest available data.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Dividend Yield | Next Earnings Date | P/E Ratio | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-TGTX
|
$63.64
|
9.5% Upside
|
Fair
|
$69.71
|
20.0% Upside
|
Undervalued
|
Great
|
0.0%
|
November 9, 2026
|
18.7x
|
13.6x
|
10.3x
|
8.243 B
|
8.445 B
|
8.5%
|
95.3%
|
5.2
|
3.9%
|
